EKF Diagnostics Holdings Plc (EKF) - Total Assets

Latest as of June 2025: GBX82.43 Million GBX ≈ $10.03K USD

Based on the latest financial reports, EKF Diagnostics Holdings Plc (EKF) holds total assets worth GBX82.43 Million GBX (≈ $10.03K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EKF book value for net asset value and shareholders' equity analysis.

EKF Diagnostics Holdings Plc - Total Assets Trend (2001–2024)

This chart illustrates how EKF Diagnostics Holdings Plc's total assets have evolved over time, based on quarterly financial data.

EKF Diagnostics Holdings Plc - Asset Composition Analysis

Current Asset Composition (December 2024)

EKF Diagnostics Holdings Plc's total assets of GBX82.43 Million consist of 34.9% current assets and 65.1% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 17.5%
Accounts Receivable GBX6.28 Million 7.7%
Inventory GBX7.39 Million 9.0%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX5.05 Million 6.2%
Goodwill GBX23.88 Million 29.2%

Asset Composition Trend (2001–2024)

This chart illustrates how EKF Diagnostics Holdings Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EKF Diagnostics Holdings Plc market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: EKF Diagnostics Holdings Plc's current assets represent 34.9% of total assets in 2024, an increase from 3.8% in 2001.
  • Cash Position: Cash and equivalents constituted 17.5% of total assets in 2024, up from 0.3% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, a decrease from 95.0% in 2001.
  • Asset Diversification: The largest asset category is goodwill at 29.2% of total assets.

EKF Diagnostics Holdings Plc Competitors by Total Assets

Key competitors of EKF Diagnostics Holdings Plc based on total assets are shown below.

Company Country Total Assets
Shenzhen New Industries Biomedical
SHE:300832
China CN¥9.58 Billion
Jafron Biomedical Co Ltd
SHE:300529
China CN¥5.54 Billion
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
China CN¥7.51 Billion
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
China CN¥3.72 Billion
Guangdong Transtek Medical Electronics Co Ltd
SHE:300562
China CN¥1.42 Billion
Emvision Medical Devices Ltd
AU:EMV
Australia AU$15.57 Million
DRGEM Corporation
KQ:263690
Korea ₩119.28 Billion
Diagnostic Medical Systems SA
PA:ALDMS
France €57.17 Million

EKF Diagnostics Holdings Plc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.62 4.60 1.74
Quick Ratio 3.47 3.08 1.34
Cash Ratio 0.00 0.00 0.00
Working Capital GBX24.71 Million GBX19.33 Million GBX15.15 Million

EKF Diagnostics Holdings Plc - Advanced Valuation Insights

This section examines the relationship between EKF Diagnostics Holdings Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.56
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) 1.1%
Total Assets GBX81.75 Million
Market Capitalization $1.39 Million USD

Valuation Analysis

Below Book Valuation: The market values EKF Diagnostics Holdings Plc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: EKF Diagnostics Holdings Plc's assets grew by 1.1% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for EKF Diagnostics Holdings Plc (2001–2024)

The table below shows the annual total assets of EKF Diagnostics Holdings Plc from 2001 to 2024.

Year Total Assets Change
2024-12-31 GBX81.75 Million
≈ $9.95K
+1.11%
2023-12-31 GBX80.85 Million
≈ $9.84K
-9.45%
2022-12-31 GBX89.29 Million
≈ $10.86K
-22.44%
2021-12-31 GBX115.12 Million
≈ $14.01K
+13.68%
2020-12-31 GBX101.27 Million
≈ $12.32K
+16.23%
2019-12-31 GBX87.13 Million
≈ $10.60K
+7.06%
2018-12-31 GBX81.38 Million
≈ $9.90K
+5.47%
2017-12-31 GBX77.16 Million
≈ $9.39K
-6.40%
2016-12-31 GBX82.43 Million
≈ $10.03K
+14.67%
2015-12-31 GBX71.89 Million
≈ $8.75K
-47.05%
2014-12-31 GBX135.78 Million
≈ $16.52K
+123.60%
2013-12-31 GBX60.72 Million
≈ $7.39K
+8.98%
2012-12-31 GBX55.72 Million
≈ $6.78K
-5.14%
2011-12-31 GBX58.73 Million
≈ $7.15K
+63.24%
2010-12-31 GBX35.98 Million
≈ $4.38K
+462.44%
2009-12-31 GBX6.40 Million
≈ $778.33
+11.48%
2008-12-31 GBX5.74 Million
≈ $698.15
+3.11%
2007-12-31 GBX5.57 Million
≈ $677.10
+7.83%
2006-12-31 GBX5.16 Million
≈ $627.94
+6.57%
2005-12-31 GBX4.84 Million
≈ $589.25
-27.25%
2004-12-31 GBX6.66 Million
≈ $809.96
+5.23%
2003-12-31 GBX6.33 Million
≈ $769.69
+1033.69%
2003-06-30 GBX558.00K
≈ $67.89
-91.32%
2002-12-31 GBX6.43 Million
≈ $782.59
+18.06%
2001-12-31 GBX5.45 Million
≈ $662.86
--

About EKF Diagnostics Holdings Plc

LSE:EKF UK Medical Devices
Market Cap
$1.39 Million
GBX11.46 Billion GBX
Market Cap Rank
#29998 Global
#743 in UK
Share Price
GBX26.55
Change (1 day)
-0.56%
52-Week Range
GBX19.80 - GBX31.90
All Time High
GBX78.21
About

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that pr… Read more